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Abstract
Vestibular schwannoma (VS) is a Schwann cell-derived tumour arising from the vestibulocochlear nerve. Although benign, 
it represents a threat to intracranial structures due to mass effect and carries a small risk of malignant transformation. VS 
therefore represents an important healthcare burden. We review the literature regarding pathogenesis, risk factors, and diag-
nosis of VS. The current and future potential management strategies are also discussed. A narrative review of all relevant 
papers known to the authors was conducted. The majority of VS remain clinically stable and do not require interventional 
procedures. Nevertheless, various surgical techniques exist for removing VS, the most common of which are translaby-
rinthine and retrosigmoid approaches. Due to surgical risks such as hearing loss, facial nerve dysfunction, post-operative 
headache, and cerebrospinal fluid leakage, a "watch and rescan" approach is adopted for most patients. Radiotherapy is a 
useful alternative and has been shown to have a similar response for growth restriction. Due to the heterogeneous nature of 
VS, there is a lack of consensus regarding management of tumours that are too large for conservative management but too 
small to indicate surgery. Emerging biologic therapies, such as Bevacizumab, Everolimus, and Lapatinib, as well as anti-
inflammatories like aspirin are promising potential treatments; however, long-term evidence of their efficacy is required. 
The knowledge base regarding VS continues to improve. With increased understanding of the pathogenesis of these tumors, 
we believe future work should focus on pharmacologic intervention. Biologic therapies aimed toward improved patient 
outcomes are particularly promising.
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Introduction
Vestibular schwannoma (VS), also called acoustic neuroma, 
is a benign Schwann cell-derived tumour arising from the 
vestibulocochlear nerve. These tumors represent 85% of 
intracranial growths arising at the cerebellopontine angle 
[1]. The Koos grading scale is commonly used to classify 
tumour size with respect to extrameatal extension and brain-
stem compression (Table 1) [2]. There is an ongoing debate 
as to the terminology of VS versus acoustic neuroma. As the 
majority of tumours arise from the vestibular aspect of the 
vestibulocochlear nerve and the tumour cells are Schwann 
cells rather than neuronal, we prefer “vestibular schwan-
noma” for this article [3].
Although benign, VS represents a risk to various intracra-
nial structures due to mass effect. The most common symp-
toms include progressive hearing loss and tinnitus which are 
reported in over 60% of patients. Larger tumours can cause 
hydrocephalus and brainstem compression leading to symp-
toms such as facial paraesthesia, vertigo, and headache [4].
VS accounts for approximately 8% of all intracranial 
tumours with an incidence of 10.4 per million per year [5]. 
The majority of tumors are unilateral and sporadic. Bilateral 
disease accounts for less than 5% of cases and is a hallmark 
of a hereditary disease related to neurofibromatosis type 2 
(NF2). Patients typically present between the ages of 20–40; 
however, those associated with NF2 often manifest earlier 
[6, 7]. The documented incidence of VS is rising, but there 
is a general consensus that this is a reflection of increased 
reporting. The now common use of magnetic resonance 
imaging (MRI) for symptoms of tinnitus and earlier care 
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seeking patient behaviours are contributing factors to these 
higher numbers [8].
This article aims to provide an up to date review of our 
understanding of the pathogenesis and diagnosis of VS with 
a focus on current management strategies. Emerging treat-
ment options are also discussed and explored.
Histologic Features
The majority of VS grow from the inferior vestibular nerve 
with rare cases arising from the superior vestibular, or coch-
lear portion of the nerve [9]. The histologic features of bipo-
lar spindle cells arranged in distinctive Antoni A and Antoni 
B tissue types are characteristic (Fig. 1).
Pathogenesis
Molecular Pathogenesis
Mutations to NF2, a tumour suppressor gene on chromosome 
22, play a vital role in the development of both sporadic and 
NF2-related disease [11]. Inactivation of the NF2 protein 
product, Merlin (schwannomin), leads to deregulation of 
various intracellular signalling pathways such as Rac1, Ras, 
PAK1, and mTORC1. Inactivation of other tumour suppres-
sor genes including LZTR1, SMARCB1, and COQ6 are also 
linked to schwannoma development (Fig. 2) [12, 13].
Although the role of NF2 mutations was reinforced by 
recent large-scale sequencing studies, there are data to sug-
gest that NF2-associated VS has a different, polyclonal 
mutation pattern [17]. This has been postulated to account 
for variance in treatment outcomes as compared to sporadic 
VS [18].
Risk Factors
Presently, much of the research on risk factors for develop-
ment of VS is focused on radiation exposure and mobile 
phone use. High dose ionizing radiation exposure (mean 
dose 4.6 ± 1.9 Gy) to the cerbellopontine angle in children 
has been linked to a higher incidence of VS after a latency 
period of 20–55 years [19]. Other studies from atomic bomb 
survivors in Japan revealed similar trends [20, 21]. The con-
trary has been observed with lower dose radiation where 
no significant link was found between the use of ionizing 
Table 1  Koos grading system for vestibular schwannoma
Koos grade Description
I Intracanalicular
II Extension into cerebellopontine 
angle, < 2 cm
III Occupies cerebellopontine angle, no brain-
stem displacement, < 3 cm
IV Brainstem displacement, > 3 cm
Fig. 1  Illustration of a histologic sample of vestibular schwannoma. 
a Antoni A tissue. Areas of tumor containing abundant spindle cells, 
with twisted nuclei and indistinctive cytoplasmic borders, arranged 
in short, well-composed bundles. Acellular pathognomonic features 
of a schwannoma, called Verocay bodies, are also seen. b Antoni B 
tissue. Areas of tumor composed of loosely arranged Schwann cells 
laden with foamy macrophages and surrounding foci of necrosis, 
cystic changes, and haemorrhage. In some tumor cells, degenerative 
nuclear changes can be seen (200 × , hematoxylin and eosin). Repro-
duced with permission from ‘’Frequency of loss of heterozygosity of 
the NF2 gene in schwannomas from Croatian patients’’. Reproduced 
with permission from Pećina-Slaus et al. [10]
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medical imaging and VS development (odds ratio (OR) 0.97, 
95% confidence interval (CI) 0.54–1.75) [22].
Multiple epidemiological studies failed to establish a 
significant link between mobile phone exposure and VS 
[23–25]. However, a 2009 systematic review and meta-
analysis evaluating long-term mobile phone use found a 
60% increase in risk for VS following ten years of ipsilateral 
mobile phone usage (OR 1.6, 95% CI 1.1–2.4) [26]. These 
findings led to a call for awareness of governments to this 
risk and even for the classification of mobile phone radiation 
as a probable human carcinogen [27, 28]. A potential flaw 
to these data is that most studies relied on patient recall of 
mobile phone usage introducing recall bias. Furthermore, 
the majority of the data relied on MRI to confirm the diag-
nosis without the analysis of tumour histopathology leaving 
the potential for inaccuracies in the reported findings. Other 
potential risk factors studied include smoking, occupation, 
allergic rhinitis, noise exposure, asthma, and eczema [29].
Diagnosis
VS is often diagnosed due to otological or neurological 
symptoms. Otological symptoms include progressive sen-
sorineural hearing loss, unilateral tinnitus, and vertigo. 
These are more common than the neurological symptoms 
such as trigeminal and facial nerve impairment, headache, 
and hydrocephalus amongst the general population [4, 30].
Up to 20% of patients presenting to Ear, Nose, and Throat 
(ENT) clinics have symptoms suggesting a lesion at the 
cerebellopontine angle [31]. Therefore, patients presenting 
with the aforementioned symptoms are generally investi-
gated with otoscopy, pure tone audiometry, and MRI of the 
internal acoustic meatus. As hearing loss typically presents 
first, the use of brainstem-evoked response audiometry has 
proven to be a useful screening tool for a suspected diag-
nosis. Despite this, it is no longer used as a first-line inves-
tigation due to high false-negatives, up to 30%, for small 
schwannomas and a false positive rate of 10% [32].
All patients presenting with unilateral tinnitus or sen-
sorineural hearing loss require MRI as the gold standard 
investigation [30, 33]. Fortnum et al. conducted a systematic 
review and cost-effectiveness study on the use of MRI in 
diagnosis of VS. Although the use of gadolinium-enhanced 
T1 weighted MRI is considered the gold standard, there was 
little difference in sensitivity and specificity compared to 
non-contrast T2 weighted scans. Furthermore, the use of 
non-contrast T2 weighted scans was deemed more cost-
effective for clinical practice [34].
Current Treatment Options
Various approaches exist to treat patients with VS. These 
include observation, termed a ‘watch and rescan’ approach, 
surgical removal, and radiotherapy. The main aim of inter-
ventional treatment is to remove or debulk the tumour to 
prevent mass effect [30].
Conservative
Observation is an accepted treatment option due to the slow 
growth rate of VS. A systematic review of 41 papers showed 
a mean tumour growth rate of 1–2 mm/year with up to 75% 
of tumours showing no further growth [35]. An observa-
tional study of 436 patients showed similar findings where 
68% of tumours did not grow during the follow-up period 
(mean 3.6 years). A third study demonstrated that patients 
Fig. 2  Mechanisms of NF2 
gene-related VS development. 
(A) In a steady-state, unphos-
phorylated merlin restricts cell 
proliferation by inhibiting Rac 
and p21-activated kinase (Pak) 
[14]. (B) NF2 gene mutations 
lead to merlin deficient cells, 
causing Rac activation lead-
ing to intercellular adhesion 
and cell proliferation [15]. 
(C) Merlin deficient cells also 
deregulate various intracellular 
pathways causing cell prolifera-
tion [12]. (D) Mutations to NF2 
also affect other pathways, seen 
in schwannomatosis, leading 
to eventual cell prolifera-
tion—although this is poorly 
understood [16]
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with NF2-related disease had higher mean growth rates 
(1.7 mm/year) as compared to sporadic tumours (1.1 mm/
year) [36]. Interestingly, one study observed that sporadic 
tumours reaching two centimetres in intracranial diameter 
are likely to continue growing. Despite this, there is no 
accepted cut-off to dictate when an observational approach 
transitions to an interventional one. Other cited risk fac-
tors for increased growth rates include the presence of an 
extracanalicular component and diagnosis at a young age; 
however, these observations are based on limited sample 
sizes from their respective studies [30, 37].
Although observation can increase the risk of tumour 
progression and mass effect, it seems a safe approach due 
to the minimal growth rate. Furthermore, delaying surgical 
intervention appears to have no increased risk in mortality 
[38]. Since growth usually manifests within the first 3 years 
after presentation, a recommended protocol for observation 
is serial MRI scans at 6 month intervals for 2 years and then 
another scan 2 years later. Following this, patients should be 
scanned every 5 years with lifelong follow-up [39].
Surgery
A range of surgical methods for VS removal are discussed 
in the literature and mainly pertain to large tumours. The 
approaches include: middle fossa (MF), extended middle 
fossa, transotic, and endoscopic resection. The translabyrin-
thine (TL) and retrosigmoid (RS) approaches are the most 
commonly used in the United Kingdom (UK) and are further 
discussed below [30]. The benefit of the MF approach for 
small tumours of greater hearing preservation versus the RS 
approach is worth mentioning. However, its use is now lim-
ited in the UK due to high risks of damage to the facial nerve 
and seizures caused by temporal lobe manipulation [40, 41].
The TL approach refers to a retroauricular incision with 
posterior extension toward the mastoid tip. This provides 
quick access to the internal acoustic canal, facial nerve, and 
tumour. A major disadvantage is poor preservation of hear-
ing, limiting the use of the TL approach to those with mini-
mal or absent preoperative hearing.
With the RS approach, a suboccipital incision exposes the 
transverse and sigmoidal sinuses, and subsequent cerebellar 
manipulation exposes the internal acoustic canal. Although 
this method is superior in preserving hearing, there is an 
increased risk of facial and cochlear nerve damage [30]. 
Of course, surgical intervention within the cranium is not 
without other risks such as meningitis, cerebellar injury, 
epilepsy, persistent headache, and cerebrospinal fluid leak-
age [42–45].
In a systematic review of 35 studies (n = 5064), it was 
reported that facial nerve dysfunction was less likely to 
occur with the RS versus TL approach for tumours greater 
than 1.5 cm [40]. Evidence exists to suggest the size of 
the tumour preoperatively is an important prognostic fac-
tor for facial nerve dysfunction postoperatively [46]. The 
study compared surgical interventions based on tumour size 
which represents a potential confounder to the data. They 
also reported postoperative headaches and CSF leak rate to 
be significantly greater following the RS approach versus 
TL. It is postulated that postoperative headaches are more 
common with the RS approach due to the incision size and 
remnant intracranial bone dust [30]. Conflicting data exists 
regarding CSF leak; Magnus et al. reported no difference 
between RS and TL approaches in 1,922 patients while Sug-
hrue et al. found the TL approach was riskier [47, 48].
Mortality and tumour recurrence did not differ between 
surgical approaches with mortality rates as low as 0.2% [48]. 
Non-specific neurological complications such as cerebellar 
dysfunction, stroke, and epilepsy were rare and occurred in 
less than 3% of cases [40]. The impact of surgery on patient 
well-being was notable as the procedure potentially delays 
a return to work for up to four months. This may lead to 
financial hardship and adverse affects on mental health [49].
Radiotherapy
There are three forms of radiotherapy treatment for VS 
management: stereotactic radiosurgery (SRS), fractionated 
stereotactic radiotherapy (FSRT), and proton beam therapy. 
SRS and FRST are most commonly used, as there is limited 
availability of proton beam therapy and inadequate evidence 
of its efficacy [50]. The main aim of radiotherapy is to pre-
vent tumour growth, therefore this is not considered a suit-
able approach for large tumours with mass effect.
Various advantages and disadvantages apply to SRS and 
FRST. SRS uses Gamma Knife technology to expose the 
tumour to a singular dose of radiation and is less applicable 
to large lesions (> 2.5 cm extracanalicular diameter) [51]. 
FRST requires numerous sessions of radiotherapy in an 
attempt to target the tumour at the most radiation-sensitive 
phase of the cell cycle for, theoretically, greater efficacy 
[52]. In addition, FRST systems are more readily available 
in hospitals and can be used on larger lesions [51].
A recent systematic review comparing FRST and SRS 
reported similar rates of tumour control with an average of 
4.8% and 5% of patients undergoing treatment requiring res-
cue therapy, respectively. Facial and trigeminal nerve dete-
rioration was less for SRS. These comparisons were based 
on limited evidence; however, and without randomised 
controlled trials (RCTs). Furthermore, only two studies 
on FRST were evaluated limiting the validity of estimates 
regarding this treatment. More studies are required to confi-
dently compare these two therapies [53].
Ranges of controlled studies demonstrate comparable 
progression-free survival rates and side effects, such as nerve 
palsies and hearing deterioration, between radiotherapy 
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and microsurgery [54–61]. A recent Cochrane review high-
lighted that these comparisons are based on low-quality evi-
dence, and no RCTs exist that compare surgery and radio-
therapy treatments [62]. Additionally, long term evidence 
(> 10 years) regarding hearing preservation following radio-
therapy is limited. Yang et al. reported an average hearing 
preservation rate of 57% from data derived from 74 articles; 
however, the average follow-up was only 41.2 months [63]. 
A more recent case-controlled study found that hearing pres-
ervation amongst patients decreases from 53% at 5 years 
to 34% at 10 and 15 years amongst all tumour grades [64]. 
This emerging evidence at increased time points suggests 
hearing may not be as well preserved as once thought, and 
loss occurs due to longer-term nerve damage as a result of 
radiation exposure. These studies also found the tumour 
Koos grade to be an independent predictor of hearing loss, 
representing a possible confounder.
The evidence presented is inconclusive regarding the best 
treatment options for all categories of VS. While most small 
tumours are managed conservatively and larger tumours with 
surgery and/or radiotherapy, there is a grey area surround-
ing best management options for tumours falling between 
categories [65]. More robust, high quality RCTs are required 
to guide treatment in these scenarios.
Emerging Treatments
As knowledge surrounding the molecular pathology of VS 
improves, targeted biologic therapies are emerging at the 
forefront of treatment. Bevacizumab, Everolimus, and Lapa-
tinib are potential options for treating VS. Furthermore, a 
link between tumour growth and non-steroidal anti-inflam-
matory medications such as aspirin has been recognised.
Bevacizumab is a monoclonal antibody and vascular 
endothelial growth factor (VEGF) inhibitor. VEGF is a key 
mediator of angiogenesis and subsequently aids tumour 
growth [66]. Plotkin et al. conducted the earliest research 
on the use of Bevacizumab in NF2 patients with progres-
sive disease. Although these studies reported improvement 
in hearing and restriction of tumour growth in over 50% of 
patients, they were based on limited sample sizes (n = 10 and 
n = 31, respectively). The later 2012 study was also based on 
retrospective data with a median treatment duration of only 
14 months [67, 68].
Since then, more promising data has arisen. In a system-
atic review on the safety and efficacy of Bevacizumab, 41% 
of patients receiving treatment had tumour regression, 20% 
experienced hearing improvement, and 69% had no further 
hearing deterioration [69]. This promising evidence supports 
the funding of Bevacizumab by NHS England for VS treat-
ment; however, these data were only based on NF2 patients. 
Therefore is difficult to know whether the results will trans-
late to the majority of the sporadic VS cases [70, 71].
Furthermore, various side effects have been reported in 
a dose-dependent relationship with Bevacizumab including 
hypertension, proteinuria, and infection [69, 72]. Although 
the most recent systematic review by the Congress of 
National Neurological Surgeons (CNS) supports the use of 
Bevacizumab, the recommendations are based on level 3 
evidence [73]. It seems clear more long-term evidence per-
taining to safety and appropriate dosing is required.
Everolimus is an mTOR complex 1 (mTORC1) inhibitor. 
mTORC1 activation has been implicated in tumour growth 
as a result of merlin deficiency. Furthermore, inhibition of 
mTORC1 has demonstrated antiangiogenic properties [74, 
75]. In theory, this seems a promising treatment; however, 
there is limited evidence of its clinical use. Phase II trials 
in NF2 patients have shown mixed results. Karajannis et al. 
found no response to Everolimus on tumour growth or hear-
ing improvements [76]. Although Goutagny et al. found a 
66.5% reduction in tumour growth during Everolimus use in 
ten NF2 patients, growth resumed following the discontinu-
ation of treatment [77]. At the time of writing, the CNS does 
not support use of Everolimus for VS management [73].
Lapatinib is an EGFR/ErbB2 inhibitor with demonstrated 
promise for tumor growth inhibition during in vitro trials 
[78]. The CNS recognises Lapatinib as a potential agent 
for growth management and hearing improvement due to 
encouraging early clinical evidence [73]. A phase II clini-
cal trial involving 21 NF2 patients found a ≥ 15% decrease 
in tumour volume in 23.5% of participants following serial 
MRI scans, and 30.8% of participants showed improved 
hearing. Only 14 of the 21 participants were eligible for 
evaluation of audiological response, however. The lack of a 
control group also limits these findings. Encouragingly, there 
were low levels of reported toxicity with Lapatinib which 
may prove important when comparing to Bevacizumab and 
its propensity for adverse side effects [79]. Again, long-
term controlled studies are required to provide more robust 
evidence.
Studies also suggest that aspirin may be beneficial to 
delay tumour growth through its anti-cyclooxygenase 2 
(COX-2) effect. A proliferative effect of COX-2 expression 
in 30 tumours was observed [80]. Another study demon-
strated the application of acetylsalicylic acid decreased 
COX-2 expression and in vitro cell growth [81]. Further-
more, a retrospective analysis followed 347 patients with VS, 
taking aspirin for unrelated reasons, to inspect the effect on 
volumetric growth versus non-aspirin users. They found a 
significant inverse association with aspirin users and tumour 
growth (OR 0.32, 95% CI 0.11–0.91) [82]. Although two 
similar retrospective analyses did not find an inverse asso-
ciation, they did not observe increased tumour growth with 
aspirin or other NSAID users [83, 84]. Therefore, a level 3 
recommendation exists in the CNS stating aspirin may be 
considered for patients undergoing observation [73].
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More recent evidence is not as promising. In a 2019 
study, tissue samples of 1048 tumours were analysed. It 
was discovered that while COX-2 expression increased with 
tumour proliferation, the use of acetylsalicylic acid did not 
alter COX-2 expression [85]. This study used tumour tissue 
retrospectively which can lend itself to selection bias since 
large tumours are more likely to be managed surgically. Most 
of the tissue samples were likely obtained from clinically 
stable tumours that may not have grown independent of the 
presence of the acetylsalicylic acid. In any case, the con-
flicting research on the use of aspirin necessitates further 
investigated through large-scale trials. Currently, there is one 
prospective phase II randomised double blind trial recruiting 
patients to assess the effect of acetylsalicylic acid on tumour 
growth and hearing preservation (NCT03079999).
Conclusions
VS is a clinically important disease with an evolving knowl-
edge base. There is now a vast scope of literature pertain-
ing to risk factors, diagnosis, and treatment. With improved 
understanding of the pathogenesis, future work should focus 
on biologic interventions due to the current risks and lack 
of high quality RCTs of different surgical and radiologic 
treatment options.
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